About Protembis
Protembis is a Healthcare company based in Aachen (Germany) founded in 2013 by Karl Von Mangoldt. It operates as a manufacturer of cerebral protection device. Protembis has raised $45.17 million across 5 funding rounds from investors including Abiomed, European Investment Bank and BMBF. Protembis offers products and services including ProtEmbo Cerebral Protection System. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is Protembis GmbH. Its competitors include Claret Medical, Emboline, Synaptive Medical, Filterlex Medical and Keystone Heart and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Protembis was founded in 2013 and is based in Aachen, Germany. Operations are centered in the medical device sector, where an implantable filter system is produced for use during minimally invasive cardiac surgeries involving the left heart. The device is introduced into the aortic arch to block embolic particles from reaching the cerebral vasculature, thereby reducing stroke risk. Focus remains on cerebral protection technologies for surgical applications.
- Headquarters Aachen, Germany
- Founders Karl Von Mangoldt
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website protembis.com
- Social LinkedIn YouTube
- Legal Name Protembis Gmbh
- Total Equity Funding$45.17M (USD)
in 5 rounds
- Latest Funding Round$21.67M (USD), Debt – Venture
Jul 2024
- InvestorsAbiomed
& 8 more
Products & Services of Protembis
Protembis offers a comprehensive portfolio of products and services, including ProtEmbo Cerebral Protection System.
Protects brain from injury during TAVR procedures effectively.
Apps and channels of Protembis
its YouTube channel Protembis has 5 subscribers and 2 videos.
Videos from Protembis
The most watched videos on Protembis's YouTube channel, Protembis (5 subscribers). Click a video to play it here.
More on Protembis.
Funding Insights of Protembis
Protembis has successfully raised a total of $45.17M across 5 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $21.67 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.17M
- Total Rounds 5
- Last Round Debt – Venture — $21.67M
- Investors Count 9
All 5 funding rounds of Protembis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $21.67M | Debt – Venture | – | – | |
| Mar 2024 | $35.17M | Series B | – | Segulah Medical Acceleration, XGEN Venture | |
| Oct 2018 | $10M | Series A | – | Abiomed, Coparion | |
| Jul 2015 | – | Seed | – | IFB Innovationsstarter, Geratherm Medical AG | – |
| Apr 2015 | – | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Protembis
Protembis has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Abiomed, European Investment Bank and BMBF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Early stage investments in life sciences are facilitated by XGEN Venture. | 2021 | xgenventure.com | Milan, Italy | |
TechVision Fonds is engaged in early-stage venture capital investments. | 2007 | techvision-fonds.de | Aachen, Germany | |
Venture capital funding for young German technology companies. | – | coparion.vc | - | |
Support is provided for Hamburg's startups through grants and capital. | – | innovationsstarter.com | Hamburg, Germany | |
Invests in medical devices, diagnostics, and healthtech for growth stages in Europe. | 2020 | segulahmedical.com | Stockholm, Sweden | |
Heart pumps are developed for blood circulation and oxygenation support. | 1981 | abiomed.com | Danvers, United States | |
Portfolio of medical devices for Diagnostic, Temperature Management, and Respiratory therapy | 1993 | geratherm.com | Geschwenda, Germany | |
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany |
Investor details for Protembis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Protembis
3 people are tracked at Protembis (3 in leadership).
| Name | Role | Group |
|---|---|---|
Karl Von Mangoldt | Co-Founder & Managing Director | Leadership |
James Hallums | Senior Vice President Business Development | Leadership |
Conrad Rasmus | Co-CEO | Leadership |
Complete people profiles for Protembis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Protembis
3 dated milestones of Protembis across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Protembis is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Venture, of $21.7M.
Competitors of Protembis
Protembis has 9 listed competitors in our database, 9 of them funded. They include Claret Medical, Emboline, Synaptive Medical, Filterlex Medical and Keystone Heart, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| claretmedical.com | 2009 | Santa Rosa, United States | $47.76M | 105 | Cerebral vascular protection systems for endovascular procedures are developed. | |
| emboline.com | 2011 | Santa Cruz, United States | $81.92M | 16 | Aortic embolic protection devices are developed for cardiovascular procedures. | |
| synaptivemedical.com | 2012 | Toronto, Canada | $76.83M | – | Planning and imaging solutions for neurosurgery are developed. | |
| filterlex.com | 2015 | Tel Aviv, Israel | $16.89M | – | Developer of an embolic protection device | |
| keystoneheart.com | 2004 | Tampa, United States | $14M | – | Embolic cerebral protection devices | |
| embrella.net | 2007 | Malvern, United States | $6.7M | – | Embolic cerebral protection is enhanced for cardiovascular procedures. | |
| transversemedical.com | 2011 | Golden, United States | $26.77M | – | Developer of a device to prevent stroke during transcatheter aortic valve replacement heart procedures | |
| invictusmed.com | 2010 | San Antonio, United States | $8.93M | – | Pediatric medical devices for infant care are developed and explored. | |
| neuramedica.com | 2014 | Oregon, United States | $1.85M | – | Bioabsorbable dural clips are developed for durotomy and spinal closures. |
Detailed competitors of Protembis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Protembis
The website of Protembis (protembis.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 52.8% vs previous month
Top companies in Neurology
10 companies that operate in the same segment as Protembis (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Protembis
Complete news archive for Protembis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protembis
Protembis was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Protembis is headquartered in Aachen, Germany. It is registered at Aachen, North Rhine-westphalia, Germany.
Protembis is a funded company, having raised a total of $45.17M across 5 funding rounds to date.
Protembis was founded in 2013 and is based in Aachen, Germany. Operations are centered in the medical device sector, where an implantable filter system is produced for use during minimally invasive cardiac surgeries involving the left heart. The device is introduced into the aortic arch to block embolic particles from reaching the cerebral vasculature, thereby reducing stroke risk. Focus remains on cerebral protection technologies for surgical applications.
Protembis's top competitors include Synaptive Medical, Emboline and Claret Medical.
Protembis offers ProtEmbo Cerebral Protection System.
Protembis has 9 investors. Key investors include Abiomed, European Investment Bank, BMBF, Geratherm Medical AG, and Segulah Medical Acceleration.
Protembis operates through Protembis Gmbh.